Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease

R. B. Geller, G. B. Vogelsang, J. R. Wingard, A. M. Yeager, W. H. Burns, G. W. Santos, R. Saral

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Five patients with acute myelocytic leukemia (AML) after combined modality therapy for Hodgkin's disease (HD) were treated with cyclophosphamide and busulfan followed by bone marrow transplantation (BMT). Four patients received allogeneic transplants from histocompatibility locus antigen (HLA)-compatible siblings and the fifth patient received an autologous marrow treated with 4-hydroperoxycyclophosphamide. Two patients died of complications of acute graft-v-host disease (GVHD) despite prophylaxis with either low-dose cyclophosphamide or cyclosporine. The remaining three patients were alive and disease-free 382, 617, and 620 days after transplant. These initial results are encouraging and more patients with treatment-related AML need to be evaluated with both allogeneic and autologous BMT to fully elucidate the potentially curative role of this intensive therapy in an otherwise fatal hematologic malignancy.

Original languageEnglish (US)
Pages (from-to)1558-1561
Number of pages4
JournalJournal of Clinical Oncology
Volume6
Issue number10
DOIs
StatePublished - Jan 1 1988

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease'. Together they form a unique fingerprint.

  • Cite this